Myers Scott Dunseth — SEC Form 4 filings
SEC reporting owner CIK 1356256. 9 Form 4 filings on record with FilingPulse; latest filed 2026-06-18.
Transaction summary — filings shown
Covers all 9 filings on record, filed 2024-03-11 to 2026-06-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 24,800 shares, $70,489 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 17.
- Largest priced transaction: purchase of 3,800 shares @ $10.82 ($41,116) in DYNAVAX TECHNOLOGIES CORP, filed 2025-08-25.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| DYNAVAX TECHNOLOGIES CORP (DVAX) | Director | 4 | 1 leg · 3,800 sh · $41,116 | — | 11 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | Director | 4 | 1 leg · 21,000 sh · $29,373 | — | 3 |
| Harpoon Therapeutics, Inc. (HARP) | Director | 1 | — | — | 3 |
Form 4 filings — Myers Scott Dunseth
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-18 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 57,100 @ $0 | EDGAR |
| 2026-02-10 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Code (U): 3,800 · Disposition to issuer (D): 31,204 · Disposition to issuer (D): 45,000 (derivative) · Disposition to issuer (D): 16,875 (derivative) · Disposition to issuer (D): 22,500 (derivative) · Disposition to issuer (D): 22,500 (derivative) · +1 more | EDGAR |
| 2025-08-25 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Purchase (P): 3,800 @ $10.82 | EDGAR |
| 2025-06-18 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 57,603 @ $0 | EDGAR |
| 2025-06-13 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Grant/award (A): 5,758 @ $0 · Grant/award (A): 28,500 (derivative) @ $0 | EDGAR |
| 2025-04-30 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Purchase (P): 21,000 @ $1.40 | EDGAR |
| 2024-11-13 | 4 | Zentalis Pharmaceuticals, Inc. (ZNTL) | Grant/award (A): 260,192 @ $0 | EDGAR |
| 2024-05-28 | 4 | DYNAVAX TECHNOLOGIES CORP (DVAX) | Grant/award (A): 5,357 @ $0 · Grant/award (A): 22,500 (derivative) @ $0 | EDGAR |
| 2024-03-11 | 4 | Harpoon Therapeutics, Inc. (HARP) | Disposition to issuer (D): 22,665 · Disposition to issuer (D): 2,033 (derivative) · Disposition to issuer (D): 4,600 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1356256 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →